1201014-01-8

Basic information

• Product Name: 4-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-benzonitrile
• Synonyms: 4-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-benzonitrile
• CAS NO: 1201014-01-8
• Molecular Weight: 363.235
• Mol File: 1201014-01-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-benzonitrile(1201014-01-8)
• EPA Substance Registry System: 4-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-benzonitrile(1201014-01-8)

Safety Data

• Hazardous Substances Data: 1201014-01-8(Hazardous Substances Data)

Upstream product

• 22190-33-6 5-bromoindoline 
• 49584-26-1 p-cyanobenzenesulfonyl chloride 

Downstream Products

• 1201014-11-0 4-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-indole-1-sulfonyl]-benzonitrile 
• 1201014-02-9 4-[5-(6-trifluoromethyl-pyridin-3-yl)-2,3-dihydro-indole-1-sulfonyl]-benzonitrile 
• 1201014-00-7 3-{4-[5-(6-trifluoromethyl-pyridin-3-yl)-2,3-dihydro-indole-1-sulfonyl]-phenyl}-4H-[1,2,4]oxadiazol-5-one 
• 1201014-03-0 N-hydroxy-4-[5-(6-trifluoromethyl-pyridin-3-yl)-2,3-dihydro-indole-1-sulfonyl]-benzamidine 
• 1201014-16-5 4-[5-(6-trifluoromethyl-pyridazin-3-yl)-2,3-dihydro-indole-1-sulfonyl]-benzonitrile 
• 1201014-13-2 4-[5-(5-methoxy-pyridin-2-yl)-2,3-dihydro-indole-1-sulfonyl]-benzonitrile 
• 1201014-12-1 4-(5-dihydroxyboranyl-2,3-dihydro-indole-1-sulfonyl)-benzonitrile 

Relevant articles and documents

ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

The invention relates to annelated pyrrolidin sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.